Protocol Ledger

NCT04457284 · Phase II · COMPLETED

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Interventional Phase II clinical trial protocol NCT04457284 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-18 Enrollment: 18 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04457284
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)18 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04457284
Protocol FieldVerified Registry Value
NCT IdentifierNCT04457284
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment18 participants (ACTUAL)
Registered Start Date2020-11-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI